1
|
Robey JMS, Maity S, Aleshire SL, Ghosh A, Yadaw AK, Roy S, Mear SJ, Jamison TF, Sirasani G, Senanayake CH, Stringham RW, Gupton BF, Donsbach KO, Nelson RC, Shanahan CS. Application of Chiral Transfer Reagents to Improve Stereoselectivity and Yields in the Synthesis of the Antituberculosis Drug Bedaquiline. Org Process Res Dev 2023; 27:2146-2159. [PMID: 38025988 PMCID: PMC10661061 DOI: 10.1021/acs.oprd.3c00287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Indexed: 12/01/2023]
Abstract
Bedaquiline (BDQ) is an important drug for treating multidrug-resistant tuberculosis (MDR-TB), a worldwide disease that causes more than 1.6 million deaths yearly. The current synthetic strategy adopted by the manufacturers to assemble this molecule relies on a nucleophilic addition reaction of a quinoline fragment to a ketone, but it suffers from low conversion and no stereoselectivity, which subsequently increases the cost of manufacturing BDQ. The Medicines for All Institute (M4ALL) has developed a new reaction methodology to this process that not only allows high conversion of starting materials but also results in good diastereo- and enantioselectivity toward the desired BDQ stereoisomer. A variety of chiral lithium amides derived from amino acids were studied, and it was found that lithium (R)-2-(methoxymethyl)pyrrolidide, obtained from d-proline, results in high assay yield of the desired syn-diastereomer pair (82%) and with considerable stereocontrol (d.r. = 13.6:1, e.r. = 3.6:1, 56% ee), providing BDQ in up to a 64% assay yield before purification steps toward the final API. This represents a considerable improvement in the BDQ yield compared to previously reported conditions and could be critical to further lowering the cost of this life-saving drug.
Collapse
Affiliation(s)
- Juliana M. S. Robey
- Medicines
for All Institute, Virginia Commonwealth University, Richmond, Virginia 23284-3068, United
States
| | - Sanjay Maity
- Medicines
for All Institute, Virginia Commonwealth University, Richmond, Virginia 23284-3068, United
States
| | - Sarah L. Aleshire
- Medicines
for All Institute, Virginia Commonwealth University, Richmond, Virginia 23284-3068, United
States
| | - Angshuman Ghosh
- R&D
Centre, TCG Life Sciences Pvt. Limited, Kolkata, WB 700091, India
| | - Ajay K. Yadaw
- R&D
Centre, TCG Life Sciences Pvt. Limited, Kolkata, WB 700091, India
| | - Subho Roy
- R&D
Centre, TCG Life Sciences Pvt. Limited, Kolkata, WB 700091, India
| | - Sarah Jane Mear
- Department
of Chemistry, Massachusetts Institute of
Technology, Cambridge, Massachusetts 02139, United States
| | - Timothy F. Jamison
- Department
of Chemistry, Massachusetts Institute of
Technology, Cambridge, Massachusetts 02139, United States
| | - Gopal Sirasani
- TCG
GreenChem, Inc., Richmond, Virginia 23219, United States
| | | | - Rodger W. Stringham
- Medicines
for All Institute, Virginia Commonwealth University, Richmond, Virginia 23284-3068, United
States
| | - B. Frank Gupton
- Medicines
for All Institute, Virginia Commonwealth University, Richmond, Virginia 23284-3068, United
States
| | - Kai O. Donsbach
- Medicines
for All Institute, Virginia Commonwealth University, Richmond, Virginia 23284-3068, United
States
| | - Ryan C. Nelson
- Medicines
for All Institute, Virginia Commonwealth University, Richmond, Virginia 23284-3068, United
States
| | - Charles S. Shanahan
- Medicines
for All Institute, Virginia Commonwealth University, Richmond, Virginia 23284-3068, United
States
| |
Collapse
|
2
|
Bashir M, Arshad M, Begum R, Aggarwal VK. Application of Enantioselective Sulfur Ylide Epoxidation to a Short Asymmetric Synthesis of Bedaquiline, a Potent Anti-Tuberculosis Drug. Org Lett 2023; 25:4281-4285. [PMID: 37284829 PMCID: PMC10278180 DOI: 10.1021/acs.orglett.3c01286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Indexed: 06/08/2023]
Abstract
A highly selective asymmetric synthesis of a potent anti-TB drug (-)-bedaquiline is accomplished using sulfur ylide asymmetric epoxidation, employing (+)-isothiocineole as an inexpensive and readily available chiral sulfide. Excellent enantioselectivity (er 96:4) and diastereoselectivity (dr 90:10) were obtained for the construction of the key diaryl epoxide, which was subsequently subjected to a highly regioselective ring opening (96:4). The synthesis was completed in nine steps starting from commercially available aldehyde in 8% overall yield.
Collapse
Affiliation(s)
- Maryam Bashir
- School
of Chemistry, University of Bristol, Cantock’s Close, Bristol BS8 1TS, U.K.
- Centre
for Organic Chemistry, School of Chemistry, University of the Punjab, Lahore 54590, Pakistan
| | - Muhammad Arshad
- Institute
of Chemistry, The Islamia University of
Bahawalpur, Bahawalpur 63100, Pakistan
| | - Robina Begum
- Centre
for Organic Chemistry, School of Chemistry, University of the Punjab, Lahore 54590, Pakistan
| | - Varinder K. Aggarwal
- School
of Chemistry, University of Bristol, Cantock’s Close, Bristol BS8 1TS, U.K.
| |
Collapse
|
3
|
Ahmad T, Gao F, Li J, Zhang Z, Song T, Yuan Q, Zhang W. Synergistic Li/Li Bimetallic System for the Asymmetric Synthesis of Antituberculosis Drug TBAJ-587. J Org Chem 2023. [PMID: 37125776 DOI: 10.1021/acs.joc.3c00705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
TBAJ-587, an analogue of the antituberculosis drug bedaquiline (BDQ), bearing a diarylquinoline skeleton retains the high bacterial potency, is less toxic, and has a better pharmacokinetic profile than the parent molecule, which has entered phase I clinical trials. In contrast to its fascinating bioactivity, however, the highly efficient synthesis of this molecule is still an unsolved challenge. Herein, the first asymmetric synthesis of TBAJ-587 based on a synergistic Li/Li bimetallic system is reported. The product could be obtained in an excellent yield of 90% and an enantiomeric ratio (er) of 80:20. Furthermore, the reaction could be conducted on a 5 g scale, and the product was obtained with 99.9:0.1 er after a simple recrystallization. The realization of this protocol will greatly aid the demand for clinical drug production.
Collapse
Affiliation(s)
- Tanveer Ahmad
- Frontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Feng Gao
- Frontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Jing Li
- Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Zhenfeng Zhang
- Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Tao Song
- Frontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Qianjia Yuan
- Frontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Wanbin Zhang
- Frontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
- Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| |
Collapse
|
4
|
Asymmetric synthesis of bedaquiline based on bimetallic activation and non-covalent interaction promotion strategies. Sci China Chem 2022. [DOI: 10.1007/s11426-022-1387-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
5
|
Mear SJ, Lucas T, Ahlqvist GP, Robey JMS, Dietz J, Khairnar PV, Maity S, Williams CL, Snead DR, Nelson RC, Opatz T, Jamison TF. Diastereoselectivity is in the Details: Minor Changes Yield Major Improvements to the Synthesis of Bedaquiline**. Chemistry 2022; 28:e202201311. [PMID: 35675114 PMCID: PMC9545417 DOI: 10.1002/chem.202201311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Indexed: 11/23/2022]
Abstract
Bedaquiline is a crucial medicine in the global fight against tuberculosis, yet its high price places it out of reach for many patients. Herein, we describe improvements to the key industrial lithiation‐addition sequence that enable a higher yielding and therefore more economical synthesis of bedaquiline. Prioritization of mechanistic understanding and multi‐lab reproducibility led to optimized reaction conditions that feature an unusual base‐salt pairing and afford a doubling of the yield of racemic bedaquiline. We anticipate that implementation of these improvements on manufacturing scale will be facile, thereby substantially increasing the accessibility of this essential medication.
Collapse
Affiliation(s)
- Sarah Jane Mear
- Department of Chemistry Massachusetts Institute of Technology Cambridge MA 02139 USA
| | - Tobias Lucas
- Department of Chemistry Johannes Gutenberg University Duesbergweg 10–14 55128 Mainz Germany
| | - Grace P. Ahlqvist
- Department of Chemistry Massachusetts Institute of Technology Cambridge MA 02139 USA
| | - Juliana M. S. Robey
- Medicines for All Institute Department of Chemistry and Life Sciences Engineering Virginia Commonwealth University Richmond Virginia 23284 USA
| | - Jule‐Philipp Dietz
- Department of Chemistry Johannes Gutenberg University Duesbergweg 10–14 55128 Mainz Germany
| | - Pankaj V. Khairnar
- Medicines for All Institute Department of Chemistry and Life Sciences Engineering Virginia Commonwealth University Richmond Virginia 23284 USA
| | - Sanjay Maity
- Medicines for All Institute Department of Chemistry and Life Sciences Engineering Virginia Commonwealth University Richmond Virginia 23284 USA
| | - Corshai L. Williams
- Department of Chemistry Massachusetts Institute of Technology Cambridge MA 02139 USA
| | - David R. Snead
- Medicines for All Institute Department of Chemistry and Life Sciences Engineering Virginia Commonwealth University Richmond Virginia 23284 USA
| | - Ryan C. Nelson
- Medicines for All Institute Department of Chemistry and Life Sciences Engineering Virginia Commonwealth University Richmond Virginia 23284 USA
| | - Till Opatz
- Department of Chemistry Johannes Gutenberg University Duesbergweg 10–14 55128 Mainz Germany
| | - Timothy F. Jamison
- Department of Chemistry Massachusetts Institute of Technology Cambridge MA 02139 USA
| |
Collapse
|
6
|
Roy D, Ali K, Panda G. Unveiling p-quinone methide (QM) chemistry to synthesize bedaquiline (TMC 207) like architectures. J Mol Struct 2021. [DOI: 10.1016/j.molstruc.2021.130493] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Kumar A, Karkara BB, Panda G. Novel candidates in the clinical development pipeline for TB drug development and their Synthetic Approaches. Chem Biol Drug Des 2021; 98:787-827. [PMID: 34397161 DOI: 10.1111/cbdd.13934] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2021] [Revised: 08/03/2021] [Accepted: 08/07/2021] [Indexed: 11/29/2022]
Abstract
Tuberculosis (TB) is an infection caused by Mycobacterium tuberculosis (Mtb) and one of the deadliest infectious diseases in the world. Mtb has the ability to become dormant within the host and to develop resistance. Hence, new antitubercular agents are required to overcome problems in the treatment of multidrug resistant-Tb (MDR-Tb) and extensively drug resistant-Tb (XDR-Tb) along with shortening the treatment time. Several efforts are being made to develop very effective new drugs for Tb, within the pharmaceutical industry, the academia, and through public private partnerships. This review will address the anti-tubercular activities, biological target, mode of action, synthetic approaches and thoughtful concept for the development of several new drugs currently in the clinical trial pipeline (up to October 2019) for tuberculosis. The aim of this review may be very useful in scheming new chemical entities (NCEs) for Mtb.
Collapse
Affiliation(s)
- Amit Kumar
- Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, UP, India
| | - Bidhu Bhusan Karkara
- Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, UP, India.,Department of Pharmaceutical Science, Vignan's Foundation for Science, Technology and Research University, Guntur, 522213, AP, India
| | - Gautam Panda
- Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, UP, India
| |
Collapse
|
8
|
Dallner G, Bentinger M, Hussain S, Sinha I, Yang J, Schwank-Xu C, Zheng X, Swiezewska E, Brismar K, Valladolid-Acebes I, Tekle M. Dehydro-Tocotrienol-β Counteracts Oxidative-Stress-Induced Diabetes Complications in db/db Mice. Antioxidants (Basel) 2021; 10:antiox10071070. [PMID: 34356303 PMCID: PMC8301068 DOI: 10.3390/antiox10071070] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2021] [Revised: 06/24/2021] [Accepted: 06/29/2021] [Indexed: 01/05/2023] Open
Abstract
Hyperglycemia, hyperlipidemia, and adiposity are the main factors that cause inflammation in type 2 diabetes due to excessive ROS production, leading to late complications. To counteract the effects of increased free radical production, we searched for a compound with effective antioxidant properties that can induce coenzyme Q biosynthesis without affecting normal cellular functions. Tocotrienols are members of the vitamin E family, well-known as efficient antioxidants that are more effective than tocopherols. Deh-T3β is a modified form of the naturally occurring tocotrienol-β. The synthesis of this compound involves the sequential modification of geranylgeraniol. In this study, we investigated the effects of this compound in different experimental models of diabetes complications. Deh-T3β was found to possess multifaceted capacities. In addition to enhanced wound healing, deh-T3β improved kidney and liver functions, reduced liver steatosis, and improved heart recovery after ischemia and insulin sensitivity in adipose tissue in a mice model of type 2 diabetes. Deh-T3β exerts these positive effects in several organs of the diabetic mice without reducing the non-fasting blood glucose levels, suggesting that both its antioxidant properties and improvement in mitochondrial function are involved, which are central to reducing diabetes complications.
Collapse
Affiliation(s)
- Gustav Dallner
- Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-17177 Stockholm, Sweden; (G.D.); (M.B.); (C.S.-X.); (X.Z.); (K.B.); (I.V.-A.)
| | - Magnus Bentinger
- Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-17177 Stockholm, Sweden; (G.D.); (M.B.); (C.S.-X.); (X.Z.); (K.B.); (I.V.-A.)
| | - Shafaat Hussain
- Department of Molecular and Clinical Medicine, University of Gothenburg, SE-41345 Gothenburg, Sweden;
- Department of Medicine, Division of Cardiology, Karolinska Institutet, SE-17177 Stockholm, Sweden;
| | - Indranil Sinha
- Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, SE-17177 Stockholm, Sweden;
| | - Jiangning Yang
- Department of Medicine, Division of Cardiology, Karolinska Institutet, SE-17177 Stockholm, Sweden;
| | - Cheng Schwank-Xu
- Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-17177 Stockholm, Sweden; (G.D.); (M.B.); (C.S.-X.); (X.Z.); (K.B.); (I.V.-A.)
| | - Xiaowei Zheng
- Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-17177 Stockholm, Sweden; (G.D.); (M.B.); (C.S.-X.); (X.Z.); (K.B.); (I.V.-A.)
| | - Ewa Swiezewska
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, PL-02-106 Warsaw, Poland;
| | - Kerstin Brismar
- Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-17177 Stockholm, Sweden; (G.D.); (M.B.); (C.S.-X.); (X.Z.); (K.B.); (I.V.-A.)
| | - Ismael Valladolid-Acebes
- Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-17177 Stockholm, Sweden; (G.D.); (M.B.); (C.S.-X.); (X.Z.); (K.B.); (I.V.-A.)
| | - Michael Tekle
- Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-17177 Stockholm, Sweden; (G.D.); (M.B.); (C.S.-X.); (X.Z.); (K.B.); (I.V.-A.)
- Department of Clinical Pharmacology, Karolinska University Hospital, SE-17177 Stockholm, Sweden
- Correspondence:
| |
Collapse
|
9
|
Barbaro L, Nagalingam G, Triccas JA, Tan L, West NP, Baell JB, Priebbenow DL. Synthesis and evaluation of pyridine-derived bedaquiline analogues containing modifications at the A-ring subunit. RSC Med Chem 2021; 12:943-959. [PMID: 34223160 DOI: 10.1039/d1md00063b] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Accepted: 04/22/2021] [Indexed: 11/21/2022] Open
Abstract
Despite promising efficacy, the clinical use of the anti-tubercular therapeutic bedaquiline has been restricted due to safety concerns. To date, limited SAR studies have focused on the quinoline ring (A-ring), and as such, we set out to explore modifications within this region in an attempt to discover new bedaquiline variants with an improved safety profile. We herein report the development of unique synthetic strategies that facilitated access to novel bedaquiline analogues leading to the discovery that anti-tubercular activity could be retained following replacement of the quinoline motif with pyridine heterocycles. This discovery is anticipated to open up multiple new avenues for exploration in the design of improved anti-tubercular therapeutics.
Collapse
Affiliation(s)
- Lisa Barbaro
- Monash Institute of Pharmaceutical Sciences, Monash University 381 Royal Parade Parkville Victoria 3052 Australia
| | - Gayathri Nagalingam
- School of Medical Sciences and Marie Bashir Institute, The University of Sydney Sydney NSW 2006 Australia
| | - James A Triccas
- School of Medical Sciences and Marie Bashir Institute, The University of Sydney Sydney NSW 2006 Australia
| | - Lendl Tan
- School of Chemistry and Molecular Bioscience, The University of Queensland St Lucia Queensland 4072 Australia.,Australian Infectious Diseases Research Centre St. Lucia Queensland 4067 Australia
| | - Nicholas P West
- School of Chemistry and Molecular Bioscience, The University of Queensland St Lucia Queensland 4072 Australia.,Australian Infectious Diseases Research Centre St. Lucia Queensland 4067 Australia
| | - Jonathan B Baell
- Monash Institute of Pharmaceutical Sciences, Monash University 381 Royal Parade Parkville Victoria 3052 Australia
| | - Daniel L Priebbenow
- School of Chemistry, The University of Melbourne Parkville Victoria 3010 Australia
| |
Collapse
|
10
|
Inhibitors of F 1F 0-ATP synthase enzymes for the treatment of tuberculosis and cancer. Future Med Chem 2021; 13:911-926. [PMID: 33845594 DOI: 10.4155/fmc-2021-0010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The spectacular success of the mycobacterial F1F0-ATP synthase inhibitor bedaquiline for the treatment of drug-resistant tuberculosis has generated wide interest in the development of other inhibitors of this enzyme. Work in this realm has included close analogues of bedaquiline with better safety profiles and 'bedaquiline-like' compounds, some of which show potent antibacterial activity in vitro although none have yet progressed to clinical trials. The search has lately extended to a range of new scaffolds as potential inhibitors, including squaramides, diaminoquinazolines, chloroquinolines, dihydropyrazolo[1,5-a]pyrazin-4-ones, thiazolidinediones, diaminopyrimidines and tetrahydroquinolines. Because of the ubiquitous expression of ATP synthase enzymes, there has also been interest in inhibitors of other bacterial ATP synthases, as well as inhibitors of human mitochondrial ATP synthase for cancer therapy. The latter encompass both complex natural products and simpler small molecules. The review seeks to demonstrate the breadth of the structural types of molecules able to effectively inhibit the function of variants of this intriguing enzyme.
Collapse
|
11
|
Calvert MB, Furkert DP, Cooper CB, Brimble MA. Synthetic approaches towards bedaquiline and its derivatives. Bioorg Med Chem Lett 2020; 30:127172. [PMID: 32291133 DOI: 10.1016/j.bmcl.2020.127172] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 04/04/2020] [Accepted: 04/04/2020] [Indexed: 01/11/2023]
Abstract
Bedaquiline is a diarylquinoline drug that demonstrates potent and selective inhibition of mycobacterial ATP synthase, and is clinically administered for the treatment of multi-drug resistant tuberculosis. Due to its excellent activity and novel mechanism of action, bedaquiline has been the focus of a number of synthetic studies. This review will discuss these synthetic approaches, as well as the synthesis and bioactivity of the numerous derivatives and molecular probes inspired by bedaquiline.
Collapse
Affiliation(s)
- Matthew B Calvert
- School of Chemical Sciences, The University of Auckland, Symonds Street, Auckland 1010, New Zealand
| | - Daniel P Furkert
- School of Chemical Sciences, The University of Auckland, Symonds Street, Auckland 1010, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Symonds Street, Auckland 1010, New Zealand
| | - Christopher B Cooper
- Global Alliance for TB Drug Development, 40 Wall Street, New York, NY 10005, USA
| | - Margaret A Brimble
- School of Chemical Sciences, The University of Auckland, Symonds Street, Auckland 1010, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Symonds Street, Auckland 1010, New Zealand.
| |
Collapse
|
12
|
Lubanyana H, Arvidsson PI, Govender T, Kruger HG, Naicker T. Improved Synthesis and Isolation of Bedaquiline. ACS OMEGA 2020; 5:3607-3611. [PMID: 32118176 PMCID: PMC7045498 DOI: 10.1021/acsomega.9b04037] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Accepted: 01/10/2020] [Indexed: 05/02/2023]
Abstract
Bedaquiline (BDQ) is the most critical pharmaceutical in the world for treating multidrug-resistant Mycobacterium tuberculosis. Despite it being highly effective, BDQ asymmetric synthesis remains a challenge. Herein, the influence of chiral bases, namely, bis(1-phenylethyl)amine, bisoxazoline, and sparteine on the diastereoselective lithiation reaction to obtain BDQ was investigated. The highest diastereoselective ratio (dr) emerged as 90:10 from the (+)-bis[(R)-1-phenylethyl] lithium amide. This is a significant improvement from the 50:50 dr achieved from the commercial synthesis. Thereafter, the desired (90:10 RS, SR) diastereomeric mixture was easily isolated via a gravity column and subjected to chiral supercritical fluid chromatography (SFC) to access the desired enantiomer (1R, 2S)-BDQ. The advantages of this procedure are enhanced diastereoselection as well as a greener, faster way to achieve excellent enantioseparation (up to 1.0 g scale).
Collapse
Affiliation(s)
- Hlengekile Lubanyana
- Catalysis
and Peptide Research Unit, University of
KwaZulu-Natal, Durban 4000, South Africa
| | - Per I. Arvidsson
- Catalysis
and Peptide Research Unit, University of
KwaZulu-Natal, Durban 4000, South Africa
- Science
for Life Laboratory, Drug Discovery & Development Platform &
Division of Translational Medicine, and Chemical Biology, Department
of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 17177, Sweden
| | - Thavendran Govender
- Catalysis
and Peptide Research Unit, University of
KwaZulu-Natal, Durban 4000, South Africa
| | - Hendrik G. Kruger
- Catalysis
and Peptide Research Unit, University of
KwaZulu-Natal, Durban 4000, South Africa
| | - Tricia Naicker
- Catalysis
and Peptide Research Unit, University of
KwaZulu-Natal, Durban 4000, South Africa
| |
Collapse
|
13
|
Rode HB, Lade DM, Grée R, Mainkar PS, Chandrasekhar S. Strategies towards the synthesis of anti-tuberculosis drugs. Org Biomol Chem 2019; 17:5428-5459. [DOI: 10.1039/c9ob00817a] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
In this report, we reviewed the strategies towards the synthesis of anti-tuberculosis drugs. They include semisynthetic approaches, resolution based strategies, microbial transformations, solid phase synthesis, and asymmetric synthesis.
Collapse
Affiliation(s)
- Haridas B. Rode
- Department of Organic Synthesis and Process Chemistry
- CSIR-Indian Institute of Chemical Technology
- Hyderabad-500007
- India
- Academy of Scientific and Innovative Research (AcSIR)
| | - Dhanaji M. Lade
- Department of Organic Synthesis and Process Chemistry
- CSIR-Indian Institute of Chemical Technology
- Hyderabad-500007
- India
- Academy of Scientific and Innovative Research (AcSIR)
| | - René Grée
- University of Rennes
- CNRS
- ISCR (Institut des Sciences Chimiques de Rennes)
- UMR 6226
- F-35000 Rennes
| | - Prathama S. Mainkar
- Department of Organic Synthesis and Process Chemistry
- CSIR-Indian Institute of Chemical Technology
- Hyderabad-500007
- India
- Academy of Scientific and Innovative Research (AcSIR)
| | - Srivari Chandrasekhar
- Department of Organic Synthesis and Process Chemistry
- CSIR-Indian Institute of Chemical Technology
- Hyderabad-500007
- India
- Academy of Scientific and Innovative Research (AcSIR)
| |
Collapse
|
14
|
Pamreddy A, Baijnath S, Naicker T, Ntshangase S, Mdanda S, Lubanyana H, Kruger HG, Govender T. Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system. RSC Adv 2018; 8:11902-11907. [PMID: 35539382 PMCID: PMC9079262 DOI: 10.1039/c8ra00984h] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 03/05/2018] [Indexed: 01/01/2023] Open
Abstract
Bedaquiline (BDQ) is the first-in-class United States Food and Drug Administration (US FDA) approved anti-tuberculosis (anti-TB) drug, which is a novel diarylquinoline antibiotic that has recently been utilized as an effective adjunct to existing therapies for multidrug-resistant tuberculosis (MDR-TB). BDQ is especially promising due to its novel mechanism of action, activity against drug-sensitive and drug-resistant tuberculosis (TB) in addition to having the potential to shorten treatment duration. Drug delivery to the central nervous system (CNS) is a major concern in TB chemotherapy, especially with the increasing cases of CNS-TB. In this study, we investigated the CNS penetration of BDQ in healthy rodent brain. Male Sprague-Dawley rats (n = 27; 100 ± 20 g) received a single 25 mg kg-1 b.w dose of BDQ via intraperitoneal (i.p.) administration, over a 24 h period. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to determine whole tissue drug concentrations and matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) was utilized to evaluate drug distribution in the brain. BDQ reached peak concentrations (C max) of 134.97 ng mL-1 in the brain at a T max of 4 h, which is within the range required for therapeutic efficacy. BDQ was widely distributed in the brain, with a particularly high intensity in the corpus callosum and associated subcortical white matter including the striatal, globus pallidus, corticofugal pathways, ventricular system, basal forebrain region and hippocampal regions. Using MALDI MSI, this study demonstrates that due to BDQ's distribution in the brain, it has the potential to target TB reservoirs within this organ.
Collapse
Affiliation(s)
- Annapurna Pamreddy
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal Westville Campus Durban 4000 South Africa
| | - Sooraj Baijnath
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal Westville Campus Durban 4000 South Africa
| | - Tricia Naicker
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal Westville Campus Durban 4000 South Africa
| | - Sphamandla Ntshangase
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal Westville Campus Durban 4000 South Africa
| | - Sipho Mdanda
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal Westville Campus Durban 4000 South Africa
| | - Hlengekile Lubanyana
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal Westville Campus Durban 4000 South Africa
| | - Hendrik G Kruger
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal Westville Campus Durban 4000 South Africa
| | - Thavendran Govender
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal Westville Campus Durban 4000 South Africa
| |
Collapse
|
15
|
Priebbenow DL, Barbaro L, Baell JB. New synthetic approaches towards analogues of bedaquiline. Org Biomol Chem 2018; 14:9622-9628. [PMID: 27714257 DOI: 10.1039/c6ob01893a] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Multi-drug resistant tuberculosis (MDR-TB) is of growing global concern and threatens to undermine increasing efforts to control the worldwide spread of tuberculosis (TB). Bedaquiline has recently emerged as a new drug developed to specifically treat MDR-TB. Despite being highly effective as a result of its unique mode of action, bedaquiline has been associated with significant toxicities and as such, safety concerns are limiting its clinical use. In order to access pharmaceutical agents that exhibit an improved safety profile for the treatment of MDR-TB, new synthetic pathways to facilitate the preparation of bedaquiline and analogues thereof have been discovered.
Collapse
Affiliation(s)
- Daniel L Priebbenow
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
| | - Lisa Barbaro
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
| | - Jonathan B Baell
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
| |
Collapse
|
16
|
Tong AST, Choi PJ, Blaser A, Sutherland HS, Tsang SKY, Guillemont J, Motte M, Cooper CB, Andries K, Van den Broeck W, Franzblau SG, Upton AM, Denny WA, Palmer BD, Conole D. 6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis. ACS Med Chem Lett 2017; 8:1019-1024. [PMID: 29057044 PMCID: PMC5642017 DOI: 10.1021/acsmedchemlett.7b00196] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Accepted: 09/22/2017] [Indexed: 12/26/2022] Open
Abstract
![]()
Bedaquiline (1) is a
new drug for tuberculosis and the first of the diarylquinoline class.
It demonstrates excellent efficacy against TB but induces phospholipidosis
at high doses, has a long terminal elimination half-life (due to its
high lipophilicity), and exhibits potent hERG channel inhibition,
resulting in clinical QTc interval prolongation. A number of structural
ring A analogues of bedaquiline have been prepared and evaluated for
their anti-M.tb activity (MIC90), with
a view to their possible application as less lipophilic second generation
compounds. It was previously observed that a range of 6-substituted
analogues of 1 demonstrated a positive correlation between
potency (MIC90) toward M.tb and drug lipophilicity.
Contrary to this trend, we discovered, by virtue of a clogP/M.tb score, that a 6-cyano (CN) substituent provides a substantial
reduction in lipophilicity with only modest effects on MIC values,
suggesting this substituent as a useful tool in the search for effective
and safer analogues of 1.
Collapse
Affiliation(s)
- Amy S. T. Tong
- Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Peter J. Choi
- Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Adrian Blaser
- Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Hamish S. Sutherland
- Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Sophia K. Y. Tsang
- Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Jerome Guillemont
- Medicinal Chemistry
Department (Infectious Diseases), Janssen Pharmaceuticals, Campus
de Maigremont, BP315, 27106 Val de Reuil Cedex, France
| | - Magali Motte
- Medicinal Chemistry
Department (Infectious Diseases), Janssen Pharmaceuticals, Campus
de Maigremont, BP315, 27106 Val de Reuil Cedex, France
| | - Christopher B. Cooper
- Global Alliance for TB Drug Development, 40 Wall Street, New York, New York 10005, United States
| | - Koen Andries
- Infectious Diseases BVBA, Janssen Pharmaceuticals, Beerse, Belgium
| | | | - Scott G. Franzblau
- Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, United States
| | - Anna M. Upton
- Global Alliance for TB Drug Development, 40 Wall Street, New York, New York 10005, United States
| | - William A. Denny
- Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Brian D. Palmer
- Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Daniel Conole
- Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| |
Collapse
|
17
|
Mishra SK, Tripathi G, Kishore N, Singh RK, Singh A, Tiwari VK. Drug development against tuberculosis: Impact of alkaloids. Eur J Med Chem 2017. [DOI: 10.1016/j.ejmech.2017.06.005] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
18
|
Chen T, Li YF, An Y, Zhang FM. Iron-Catalyzed α-Arylation of Deoxybenzoins with Arenes through an Oxidative Dehydrogenative Approach. Org Lett 2016; 18:4754-7. [DOI: 10.1021/acs.orglett.6b02516] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Tao Chen
- State Key Laboratory of Applied
Organic Chemistry and Department of Chemistry, Lanzhou University, Lanzhou 730000, P. R. China
| | - Yi-Fan Li
- State Key Laboratory of Applied
Organic Chemistry and Department of Chemistry, Lanzhou University, Lanzhou 730000, P. R. China
| | - Yang An
- State Key Laboratory of Applied
Organic Chemistry and Department of Chemistry, Lanzhou University, Lanzhou 730000, P. R. China
| | - Fu-Min Zhang
- State Key Laboratory of Applied
Organic Chemistry and Department of Chemistry, Lanzhou University, Lanzhou 730000, P. R. China
| |
Collapse
|
19
|
Baijnath S, Shobo A, Bester LA, Singh SD, Kruger G, Arvidsson PI, Naicker T, Govender T. Neuroprotective potential of Linezolid: a quantitative and distribution study via mass spectrometry. J Mol Histol 2016; 47:429-35. [DOI: 10.1007/s10735-016-9685-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Accepted: 06/13/2016] [Indexed: 10/21/2022]
|
20
|
Douša M, Reitmajer J, Lustig P, Štefko M. Effect of Chromatographic Conditions on Enantioseparation of Bedaquiline Using Polysaccharide-based Chiral Stationary Phases in RP-HPLC. J Chromatogr Sci 2016; 54:1501-1507. [DOI: 10.1093/chromsci/bmw050] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Revised: 01/27/2016] [Indexed: 11/13/2022]
|
21
|
Qiao CJ, Wang XK, Xie F, Zhong W, Li S. Asymmetric Synthesis and Absolute Configuration Assignment of a New Type of Bedaquiline Analogue. Molecules 2015; 20:22272-85. [PMID: 26690407 PMCID: PMC6331863 DOI: 10.3390/molecules201219846] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Revised: 12/04/2015] [Accepted: 12/07/2015] [Indexed: 12/02/2022] Open
Abstract
Bedaquiline is the first FDA-approved new chemical entity to fight multidrug-resistant tuberculosis in the last forty years. Our group replaced the quinoline ring with a naphthalene ring, leading to a new type of triarylbutanol skeleton. An asymmetric synthetic route was established for our bedaquiline analogues, and the goal of assigning their absolute configurations was achieved by comparison of experimental and calculated electronic circular dichroism spectra, and was confirmed by the combined use of circular dichroism and NMR spectroscopy.
Collapse
Affiliation(s)
- Chang-Jiang Qiao
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.
- Laboratory of Computer-Aided Drug Design & Discovery, Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China.
| | - Xiao-Kui Wang
- Laboratory of Computer-Aided Drug Design & Discovery, Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China.
| | - Fei Xie
- Laboratory of Computer-Aided Drug Design & Discovery, Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China.
| | - Wu Zhong
- Laboratory of Computer-Aided Drug Design & Discovery, Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China.
| | - Song Li
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.
- Laboratory of Computer-Aided Drug Design & Discovery, Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China.
| |
Collapse
|
22
|
Kong DL, Huang Y, Ren LY, Feng WH. A highly efficient way to recycle inactive stereoisomers of Bedaquiline into two previous intermediates via base-catalyzed Csp3Csp3 bond cleavage. CHINESE CHEM LETT 2015. [DOI: 10.1016/j.cclet.2015.04.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|